Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.54 |
| ▸ | JAK2 | O60674 | 5/20 | 0.37 |
| ▸ | JAK1 | P23458 | 5/20 | 0.37 |
| ▸ | TYK2 | P29597 | 5/20 | 0.37 |
| ▸ | JAK3 | P52333 | 5/20 | 0.37 |
| ▸ | EED | O75530 | 1/20 | 0.31 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.31 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22858782 | 0.92 | MAP4K1 (0.55) | MAP4K1JAK2JAK1TYK2JAK3 | |
| SCHEMBL22859064 | 0.92 | MAP4K1 (0.55) | MAP4K1JAK2JAK1TYK2JAK3 | |
| SCHEMBL22858815 | 0.90 | MAP4K1 (0.55) | MAP4K1JAK2JAK1TYK2JAK3 | |
| SCHEMBL22859204 | 0.89 | MAP4K1 (0.52) | MAP4K1JAK2JAK1TYK2JAK3 | |
| SCHEMBL22858986 | 0.89 | MAP4K1 (0.54) | MAP4K1JAK2JAK1TYK2JAK3 | |
| SCHEMBL22859206 | 0.88 | MAP4K1 (0.51) | MAP4K1JAK2JAK1TYK2JAK3 | |
| SCHEMBL29608799 | 0.86 | MAP4K1 (0.52) | MAP4K1JAK2JAK1TYK2JAK3 | |
| SCHEMBL22858808 | 0.84 | MAP4K1 (0.49) | MAP4K1JAK2JAK1TYK2JAK3 | |
| SCHEMBL22859004 | 0.84 | MAP4K1 (0.78) | MAP4K1JAK2JAK1TYK2JAK3 | |
| SCHEMBL29608359 | 0.84 | MAP4K1 (0.78) | MAP4K1JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021000925-A1 | PYRROLO [2, 3-b] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2021-01-07 | — | — | WO | disclosed |